FDA reviewers have strong incentive to restrict access to new drugs and other therapies until there is extensive evidence that the therapies are safe. These incentives work against patients suffering painful or terminal diseases that have no effective therapy. And throughout the COVID-19 pandemic the FDA was continually in the spotlight for its poorly handling many potential COVID-19 remedies.
Why do we have an FDA?
Hosted on Acast. See acast.com/privacy for more information.
